Categories
Cancer Clinical trials Medicine

Evangelos Michelakis on dichloroacetate (DCA) and glioblastoma

As a followup to my rather “epic post” on dichloroacetate, I thought I’d just post a brief follow up. A reader sent me this video of Evangelos Michelakis, the investigator who has been testing DCA in the clinic and who did the study testing DCA against gliblastoma, describing his results:

It’s always interesting to hear research results “straigh from the horse’s mouth, so to speak.”

By Orac

Orac is the nom de blog of a humble surgeon/scientist who has an ego just big enough to delude himself that someone, somewhere might actually give a rodent's posterior about his copious verbal meanderings, but just barely small enough to admit to himself that few probably will. That surgeon is otherwise known as David Gorski.

That this particular surgeon has chosen his nom de blog based on a rather cranky and arrogant computer shaped like a clear box of blinking lights that he originally encountered when he became a fan of a 35 year old British SF television show whose special effects were renowned for their BBC/Doctor Who-style low budget look, but whose stories nonetheless resulted in some of the best, most innovative science fiction ever televised, should tell you nearly all that you need to know about Orac. (That, and the length of the preceding sentence.)

DISCLAIMER:: The various written meanderings here are the opinions of Orac and Orac alone, written on his own time. They should never be construed as representing the opinions of any other person or entity, especially Orac's cancer center, department of surgery, medical school, or university. Also note that Orac is nonpartisan; he is more than willing to criticize the statements of anyone, regardless of of political leanings, if that anyone advocates pseudoscience or quackery. Finally, medical commentary is not to be construed in any way as medical advice.

To contact Orac: [email protected]

6 replies on “Evangelos Michelakis on dichloroacetate (DCA) and glioblastoma”

Well I’m glad these guys put to rest the notion that compounds in the public domain which are discovered to be useful in the fight against cancer can be brought to market without industry support.

I mean, no one here has any doubt that if Pfizer had been able to patent DCA three years ago we would be at exactly the same point in the process of bringing it to the cancer patients who need it. Pfizer would have limited internal funding of clinical trials to $500,000 per year, right? And of course, out of the goodness of their hearts, given it’s about as difficult to make as iodized table salt, they would have sold it for pennies per daily dose.

Uh huh. That’s how it would have played out…

What? What’s that, DaveScot? I can’t hear you over the sound of goalposts being hastily dragged.

Now that oracle has at least reason to doubt his on misdirected and wrongly negative pontifications, how about considering Metformin, another generic shown to act against cancer’s metabolism,, along with DCA ?? Two attacks on cancer’s metabolism ,, 1+1 might equal 100. At least please try a rodent trial !! Both would slow/act against cancers glycolysis , they would seem very likely candidates to be considered for use together. If not, then why not?

CLINICAL BIOCHEMISTRY RESEARCH CENTER
DIRECTOR:PROF:KYRIAKOS PISPIRIGOS

Dear Eyaggelos,

We would like to informing you that, the compound Dichloroacetate (DCA), we have been working and the evaluation for the subacute toxicity results, concerns
Cardio-Liver and kidney results.
In case you are interest, please give a call, OK?

Best Regards

Kyriakos Pispirigos PhD

CLINICAL BIOCHEMISTRY RESEARCH CENTER
DIRECTOR:PROF:KYRIAKOS PISPIRIGOS

Dear Eyaggelos,

We would like to informing you that, the compound Dichloroacetate (DCA), we have been working and the evaluation for the subacute toxicity results, concerns
Cardio-Liver and kidney results.
In case you are interest, please give a call, +302610273277 OK?

Best Regards

Kyriakos Pispirigos PhD

Comments are closed.